Elderly-onset RA Patient

Meet Pradeep, a 69-year-old elderly-onset RA patient,^1-4 diagnosed just months after his retirement.

Elderly patients such as Pradeep benefit from long-term disease control and better drug survival with Enbrel^®1,2

• Improvements in disease activity and function were sustained up to 4 years in elderly patients with recent-onset RA and up to 6 years with late-stage RA^1,†

• Risk of discontinuation due to severe adverse drug reactions in elderly patients was lower with Enbrel^® compared to both adalimumab and infliximab^2,‡

From subset analyses of 4 RCTs and 2 long-term extension studies that evaluated a total of 2402 patients with RA.^1,†

Observed ACR Response in Recent-onset RA Patients Treated With Open-label Enbrel^®1

Adapted from Bathon MJ, et al. 2006.

Please consult the LPD for contraindications, warnings, precautions and other important safety information.

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.

*From a prospective observational study of 665 patients diagnosed with early RA (symptomatic for <12 months) who were divided into 2 groups: young-onset (<58 years) and late-onset (≥58 years) and followed for over 5 years. Over 5 years, late-onset RA was associated with less frequent treatment with biologics compared with young-onset RA: 7.4% versus 24.6%, respectively, P<0.001.⁷

^†From subset analyses of 4 randomised controlled clinical studies (n=1353) and 2 long-term extension studies (n=1049) of Enbrel^®.¹

Study design: Bathon MJ, et al. 2006.

Study objectives included the assessments of: whether the efficacy and safety of Enbrel^® are similar in elderly (≥65 years) and younger (<65 years) subjects; whether Enbrel^® treatment is effective in both elderly and younger subjects who have recent-onset (early) RA or DMARD-refractory (late-stage) RA.¹

For the extension studies, ACR responses were presented as ‘observed cases’. Time points were measured from baseline of the extension and did not include study drug exposure in the initial studies. All subjects in the extensions received Enbrel^® 25 mg BIW.¹

The ERA study (ERA, 016.0012), which compared Enbrel^® and MTX therapy, was the sole study through which subjects entered the recent-onset RA extension. Efficacy assessments were measured relative to the baseline of the ERA study.¹

^‡From a 14-year retrospective longitudinal analysis of 146 patients with RA followed in an outpatient clinic starting bDMARDs after the age of 65 years.²

ACR, American College of Rheumatology; AS, ankylosing spondylitis; bDMARD, biologic disease-modifying antirheumatic drug; BIW, twice a week; DMARD, disease-modifying anti-rheumatic drug; ERA, Early Rheumatoid Arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SmPC, summary of product characteristics.

References: